Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for CardioGenics Holdings Inc. (CGNH : OTC)
 
 • Company Description   
CardioGenics Inc., through its operating subsidiaries, develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care Analyzer, a Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. The Company has also developed a method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. CardioGenics's principal offices are located in Mississauga, Ontario, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.00 Daily Weekly Monthly
20 Day Moving Average: 150 shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta: 2.63
52 Week High: $0.00
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6295 Northam Drive Unit 8
-
Mississauga,A6 L4V 1W8
CAN
ph: 905-673-8501
fax: 905-673-9865
invest@jagnotes.com http://www.cardiogenics.com
 
 • General Corporate Information   
Officers
J Neil Tabatznik - Director/Acting Chairman
Yahia Gawad - Director & Chief Executive Officer
James A. Essex - Chief Financial Officer
Linda J. Sterling - Director & Secretary
Karim Murabet - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 14160X203
SIC: 7389
Fiscal Year
Fiscal Year End: October
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: (:1)
Beta: 2.63
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
01/31/26 - -
10/31/25 - -
07/31/25 - -
ROA
01/31/26 - -
10/31/25 - -
07/31/25 - -
Current Ratio
01/31/26 - -
10/31/25 - -
07/31/25 - -
Quick Ratio
01/31/26 - -
10/31/25 - -
07/31/25 - -
Operating Margin
01/31/26 - -
10/31/25 - -
07/31/25 - -
Net Margin
01/31/26 - -
10/31/25 - -
07/31/25 - -
Pre-Tax Margin
01/31/26 - -
10/31/25 - -
07/31/25 - -
Book Value
01/31/26 - -
10/31/25 - -
07/31/25 - -
Inventory Turnover
01/31/26 - -
10/31/25 - -
07/31/25 - -
Debt-to-Equity
01/31/26 - -
10/31/25 - -
07/31/25 - -
Debt-to-Capital
01/31/26 - -
10/31/25 - -
07/31/25 - -
 

Powered by Zacks Investment Research ©